StockData
ISPCNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31

iSpecimen Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.91−0.01 (-0.75%)

Close on Oct 19, 2026

Market cap
$1.27M
P/E (TTM)
–
Dividend yield
–

About iSpecimen

Services-Commercial Physical & Biological Research, SIC 8731

iSpecimen Inc. operates an online marketplace platform that connects life science researchers with healthcare provider organizations supplying human biospecimens, including biofluids, tissues, and living cells, along with associated clinical data. The platform harmonizes de-identified patient and specimen data from electronic medical records, laboratory information systems, and biobank inventory systems into a centralized dataset. This system enables researchers to search for specific cohorts, request quotes, configure custom collections, and place orders. The company serves clients across industry, academia, and government institutions.

The company operates a global network of centralized healthcare supply partners. As of December 31, 2025, its marketplace platform had harmonized data covering approximately 19 million patient records, 105 million clinical specimen records, 1.4 million banked specimen records, and 1.2 million medical conditions. Since inception, the business has delivered more than 218,000 specimens across more than 3,500 projects. iSpecimen is headquartered in Woburn, Massachusetts.

Summary of the business section of iSpecimen's latest annual report, written by StockData.

Company profile

Company

Legal name
iSpecimen Inc.
Headquarters
Woburn, MA
Address
8 Cabot Road, Suite 1800 08101
Phone
(781) 301-6700
Employees
53, Dec 31, 2023
Industry
Services-Commercial Physical & Biological Research
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Bush & Associates CPA LLC, Las Vegas, Nevada

Stock & identifiers

Ticker
ISPC
Exchange
Nasdaq
IPO date
Jun 21, 2021
Shares outstanding
3M, Aug 14, 2026
Public float
$2.45M, Jun 30, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-40 reverse, May 18, 2026; 1-for-40 reverse, Apr 28, 2026; 1-for-20 reverse, Oct 1, 2024; 1-for-20 reverse, Sep 16, 2024
SEC CIK
1558569
CUSIP
45032V306
ISIN
US45032V3069
EIN
27-0480143

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Robert Bradley LimChief Executive Officer, Director–
Yuying LiangChief Financial Officer–
Arphing LeeDirector–

Employees

Headcount reported in annual reports

“As of December 31, 2023, we had fifty-three employees (not including co-ops or summer interns), ten of whom were engaged in research and development activities, eleven of whom were engaged in sales and marketing activities, eighteen of whom were engaged in operations and fulfillment activities, five of whom were engaged in supply development and manag”

Corporate history

Events identified from SEC filings